Tobramycine ( DrugBank: Tobramycine )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-013660-39-FR (EUCTR)	10/09/2009	27/11/2009	Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ®	Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ®	Mucoviscidose MedDRA version: 12.0;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung	Product Name: Nebcinal INN or Proposed INN: tobramycine Trade Name: Tobi Product Name: Tobi INN or Proposed INN: tobramycine	Erempharma SAS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
2	EUCTR2005-002035-28-LT (EUCTR)	19/09/2005	24/08/2005	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects	pulmonary P aeruginosa infection in patient with cystic fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Product Name: Tobramycin Inhalation Powder Product Code: TIP INN or Proposed INN: Tobramycine	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	220	Phase 3	Lithuania